Director, Key Opinion Leader Marketing, Rare Disease

Ipsen•Cambridge, MA

11d•$190,500 - $265,000

About The Position

Ipsen's Rare Disease franchise has been expanding through both organic growth and acquisitions. From a marketing standpoint, there is a critical need for excellence in strategic planning and excellence in execution to clearly define how we will best drive education of appropriate healthcare providers, deliver successful launches, and innovate for patients in complex and competitive therapeutic areas. The Director, Key Opinion Leader Marketing, Rare Disease is a strategic leader within the U.S. Rare Liver Marketing team, responsible for defining and advancing the peer-to-peer engagement strategy across the portfolio. This role serves as the architect of Ipsen's external expert engagement ecosystem, shaping how scientific leaders, advocates, and peer influencers are engaged to advance disease-state education, support earlier diagnosis, inform brand strategy, and drive adoption across existing and future portfolio assets. This role requires deep expertise in external expert engagement, peer-to-peer education, and congress strategy, as well as the scientific acumen, executive presence, and cross-functional leadership necessary to influence senior stakeholders and drive portfolio-wide impact. This role owns the strategic direction and governance of speaker bureau excellence, KOL engagement, peer to peer education, and congress activation across the U.S. rare disease portfolio. This individual ensures a coordinated and highly credible external engagement approach that elevates Ipsen's scientific leadership and commercial impact.

Requirements

Significant experience (12+ years) of commercial pharma experience, including U.S. peer-to-peer, speaker, or HCP marketing roles in rare disease and/or specialty markets
Proven success managing a speaker bureau, delivering peer-to-peer programs and working with KOLs
Proven experience planning and executing local, regional, and national congresses
Experience building peer-to-peer and speaker programs in rare or ultra-rare diseases
Strong understanding of medical, legal, and regulatory (MLR) requirements governing peer to peer programs
Strong communication and interpersonal skills along with the ability to influence others
Demonstrated ability to lead cross-functionally and influence senior stakeholders
Strong scientific/medical aptitude and experience including knowledge of complex therapeutic areas and dynamic treatment landscapes
Mentally agile and solutions-oriented, with the ability to navigate ambiguity, adapt quickly, and drive practical solutions in a dynamic environment
Ability to work with multiple internal cross-functional teams and successfully manage multiple projects simultaneously
Knowledge of regulations associated with promotion and industry-supported scientific education activities.
Working within an environment of strict compliance to all appropriate regulatory guidelines
Demonstrated success in project, vendor, and experience managing large budgets

Nice To Haves

Advanced degree (MBA, PharmD, MSc) preferred

Responsibilities

Own and evolve the enterprise peer-to-peer engagement strategy across the U.S. Rare Disease portfolio, ensuring alignment with portfolio growth objectives, competitive dynamics, and future launch priorities
Establish portfolio-level KOL, speaker, and advocate engagement frameworks, segmentation approaches, and investment priorities that maximize scientific influence and educational impact
Build a credible, science-driven peer to peer offering aligned to portfolio priorities including tools and resources for TLL team
Prioritize peer-to-peer programs and channels to expand reach and frequency across key stakeholders
Build and manage congress roadmap, capabilities, and continually improve associated processes
Ensure a single, cohesive peer to peer experience aligned to brand strategy and priorities
Shape how peer influence is leveraged across the customer journey to support disease-state awareness, diagnosis acceleration, treatment adoption, and launch readiness
Own and continuously evolve the portfolio speaker bureau strategy, governance, and operating model, ensuring alignment to business priorities and maximizing the impact of peer-to-peer engagement investments
Establish governance and oversight for speaker engagement, contracting, fair market value rates, utilization, and HCP transparency practices across the rare disease portfolio.
Define and lead the portfolio congress strategy, including prioritization of investments, scientific engagement plans, sponsorship opportunities, and cross-brand activation designed to maximize organizational impact
Direct the design and execution of integrated congress and peer-to-peer engagement plans that advance disease-state education, strengthen scientific leadership, and support portfolio growth objectives.
Lead strategic partnerships with agencies and external vendors, ensuring delivery of innovative, high-impact engagement programs while optimizing resource allocation and return on investment.
Partner with Medical, PRC, Legal, and Business Ethics to establish governance frameworks and ensure compliant execution of peer engagement activities across the portfolio.
Serve as the organization's center of excellence for peer engagement strategy, establishing standards, governance, and best practices across the rare disease portfolio
Define KPIs and measurement to optimize speaker and congress program performance and ROI
Own portfolio speaker bureau and congress budget planning and resource allocation
Ensuring on-time and on-budget delivery of congresses, and sponsorships
Synthesize insights from KOL interactions, congress engagement, speaker bureau activity, and competitive intelligence to inform portfolio strategy, launch planning, and business decision-making
Establish clear governance, decision-making, and prioritization across the team and partners
Drive alignment with Brand, Sales, TLL, Medical, PRC and Business ethics
Influence senior leadership through data-driven recommendations regarding market dynamics, emerging scientific trends, KOL sentiment, and external stakeholder priorities